Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balcinrenone/dapagliflozin - AstraZeneca

Next Previous
Drug Profile

Balcinrenone/dapagliflozin - AstraZeneca

Alternative Names: Dapagliflozin/balcinrenone - AstraZeneca

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Acetamides; Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Benzoxazines; Cardiovascular therapies; Chlorobenzenes; Fluorinated hydrocarbons; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
  • Mechanism of Action Mineralocorticoid receptor modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure; Renal failure

Most Recent Events

  • 31 May 2025 AstraZeneca initiates a phase I trial (In volunteers) in the United Kingdom (PO) (NCT06651021)
  • 20 May 2025 AstraZeneca plans a phase I trial (In volunteers) in United Kingdom (PO, Capsule), in May 2025 (NCT06979388)
  • 09 May 2025 AstraZeneca completes the phase-II MIRO-CKD trial for Renal failure (Treatment-experienced) in USA, Austria, Brazil, Bulgaria, Canada, China, Italy, Japan, Malaysia, Poland, Spain, Taiwan, Turkey, United Kingdom and Vietnam (PO), (NCT06350123)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top